Context Therapeutics Inc.
09/02/2025 | Press release | Distributed by Public on 09/02/2025 05:32
Failure to Satisfy Listing Rule (Form 8-K)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On August 28, 2025, Context Therapeutics Inc. (the "Company") received written notice (the "Extension Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the "Extension Deadline"), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company's common stock.
As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that the Company was not in compliance with the Minimum Bid Price Rule because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Rule. These options include effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will regain compliance with the Minimum Bid Price Rule by the Extension Deadline.
Context Therapeutics Inc. published this content on September 02, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 02, 2025 at 11:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]